Ironwood Pharmaceuticals (IRWD) Jefferies 2024 Global Healthcare Conference summary

Business overview and product portfolio

• Focuses on gastrointestinal (GI) diseases with a leading product, LINZESS, for IBS-C and chronic constipation, holding the top US market share and generating significant profits.

• Acquired VectivBio for over $1 billion, adding apraglutide for short bowel syndrome (SBS) and expanding the rare GI disease portfolio.

• Apraglutide showed strong phase III results, meeting primary and key secondary endpoints, with plans to file and launch by end of next year.

• Pipeline includes CNP-104 for primary biliary cholangitis, with phase II results expected in Q3.

Apraglutide clinical data and physician feedback

• Physicians responded very positively to apraglutide data, especially its strong efficacy and rapid onset of benefit.

• Once-weekly dosing and safety profile comparable to placebo are seen as major advantages.

• High responder rates and potential for multiple days off parenteral nutrition are key clinical benefits.

• Physicians value overall patient benefit and compliance over small differences in efficacy between competitors.

Competitive landscape and market positioning

• Apraglutide's trial was the largest globally, making cross-trial comparisons with Gattex and Glempa challenging due to different endpoints and sample sizes.

• Apraglutide achieved a 2x placebo response, considered best-in-class by clinicians.

• Once-weekly administration is expected to improve compliance compared to daily or twice-weekly competitors.

• Market is split between CIC and stoma patients, with GLP-2s effective in both groups.